Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors

Clin Cancer Res. 2005 Aug 15;11(16):5668-70. doi: 10.1158/1078-0432.CCR-05-1055.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Kommentar

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / genetics
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • DNA Mutational Analysis
  • ErbB Receptors / genetics*
  • Gefitinib
  • Genotype
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Mutation*
  • Prognosis
  • Protein Kinase Inhibitors / therapeutic use
  • Quinazolines / therapeutic use*
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Quinazolines
  • ErbB Receptors
  • Gefitinib